Neonatal screening for severe combined immunodeficiency.

Area of Science:

• Immunology
• Genetics
• Public Health

Background:

• Severe combined immunodeficiency (SCID) is a group of rare genetic disorders characterized by profound defects in T-cell immunity.
• Early detection and treatment of SCID are critical to prevent life-threatening infections and improve long-term outcomes.
• Population-based newborn screening programs are expanding to include SCID and related disorders.

Purpose of the Study:

• To review the rationale, development, and implementation of SCID newborn screening programs.
• To highlight current and future challenges in SCID screening and management.
• To assess the effectiveness of T-cell receptor excision circle (TREC) testing in identifying infants with SCID.

Main Methods:

• Review of existing literature and data on SCID newborn screening programs.
• Analysis of early results from pilot states utilizing TREC testing.
• Evaluation of the clinical validity and utility of TREC as a biomarker for T-cell lymphopenia.

Main Results:

• TREC testing has been successfully integrated into state public health newborn screening panels.
• TREC testing demonstrates clinical validity as a biomarker for impaired T-lymphocyte production or increased loss.
• Pilot programs have successfully detected SCID and other T-cell lymphopenic disorders, enabling timely referrals for treatment.

Conclusions:

• Routine newborn screening for SCID using TREC testing facilitates presymptomatic diagnosis.
• Integrated public health programs can effectively implement TREC-based SCID screening.
• Prompt diagnosis and treatment of SCID and related disorders lead to improved patient outcomes and a better understanding of these conditions.